Ann: Strategic Investment from Sichuan Hebang Biotechnology, page-11

Looking back at the share price for last many weeks, many were concerned about a cheap capital raise. Before any leaks, it was around 0.4c since mid July. Now, with the issue price set at a 50% premium (0.6c/0.4c), It's fair enough.

Some folks were saying the Hebang deal was dead and ex-directors were jumping ship. Without Hebang’s backing, I wouldn’t be holding this stock long-term without its firm commitment on the phosphate project. Now even better with LFP still in play.

My worry was who would fund the feasibility study without knowing Hebang’s commitment to offtake. Further on, a BOA without a solid study results in cheap sales. Now, it’s clear that they are funding the study and the offtake deal will be assessed fairly based on the study.

Honestly, I can’t see a better outcome, or please enlighten me.